health

World champion Jepchirchir fails drugs test

World champion Jepchirchir fails drugs test

Reigning world women's marathon champion Peres Jepchirchir is provisionally suspended by the Athletics Integrity Unit after a sample tests positive for EPO.

Olympic and World Championships marathon gold medallist Peres Jepchirchir has been provisionally suspended by the Athletics Integrity Unit after an out-of-competition sample tested positive for EPO.

Kenyan Jepchirchir provided the sample prior to winning the Sydney Marathon on 30 August 2026.

The 33-year-old clocked a time of two hours, 18 minutes and 31 seconds to win in Sydney.

EPO, or erythropoietin, is a natural substance produced within the kidneys that stimulates the creation of new red blood cells.

If injected, it is only detectable in the urine or blood for a short window of time, and increases the amount of red blood cells, which carry oxygen to the muscles, in the blood stream.

Jepchirchir became the Olympic women's marathon champion at the 2020 Tokyo Olympics and returned to the Japanese capital to win the World Championships in September 2025.

She broke the women's half-marathon world record in 2017 and on three occasions in 2020.

In addition to Sydney, her other major wins came at the New York Marathon in 2021, the Boston Marathon in 2022 and the London Marathon in 2024.

Jepchirchir won the Sydney race, which became the seventh world major in 2025, by more than three minutes from compatriot Irene Chepet Cheptai.

She provided the sample which tested positive for EPO while in Kenya prior to the race.

  • world
  • champion
  • jepchirchir
  • test
  • drug
  • woman
  • peres
  • athletics

Summaries and tags are generated automatically. Stay informed with VidiaNews.

Related news

Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs
health

Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs

World’s second largest brewer says use of drugs such as Wegovy can reduce desire to drink alcohol Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider. The world’s second largest brewer sent a presentation to British hospitality customers earlier this month warning that GLP-1 use – led by Ozempic and Wegovy – can reduce the desire to drink alcohol, which could lead to “fullness and fewer serves” of pints in pubs and bars.

Read →
India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
health

India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’

Case filed in 2022 by patient unable to afford medicine leads to cap on drug prices for millions who face ruin if diagnosed The Indian government has moved to reduce the price of cancer drugs after a retired bank clerk took her case to the supreme court. From next month, 137 cancer drugs in India will be cheaper as the government tries to tackle the tragedy of poorer patients either forgoing treatment, selling land or falling into debt to meet the high cost of some medicines, which are making large profits for hospitals and pharmacists.

Read →
L’Oreal says weight loss drugs are impacting beauty and skin care sales
health

L’Oreal says weight loss drugs are impacting beauty and skin care sales

The company’s head Nicolas Hieronimus said the beauty market was proving resilient in a challenging global context, and that the use of GLP-1s was “a very important phenomenon for us”. The use of GLP-1s has boomed in popularity in recent years, after drugs developed to treat diabetes such as Ozempic, Wegovy and Mounjaro were found to also lead to significant weight loss because they supress the appetite.

Read →